Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 34
- Registration Number
- NCT04142060
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Universitari Vall d' Hebrón, Barcelona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Julie Graff, MD
- Target Recruit Count
- 32
- Registration Number
- NCT04116775
- Locations
- 🇺🇸
VA Portland Health Care System, Portland, Oregon, United States
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04094519
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04087174
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Conditions
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT04076059
- Locations
- 🇨🇳
Site CN86009, Changsha, China
🇨🇳Site CN86025, Fuzhou, China
🇨🇳Site CN86010, Shanghai, China
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04052204
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 979
- Registration Number
- NCT04034095
- Locations
- 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 100
- Registration Number
- NCT04015622
- Locations
- 🇨🇦
BC Cancer - Centre for the North, Prince George, British Columbia, Canada
🇨🇦BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna, British Columbia, Canada
🇨🇦BC Cancer - Surrey Centre, Surrey, British Columbia, Canada
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT03999515
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03939689
- Locations
- 🇺🇸
Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.